Overview


According to FutureWise analysis the market for MiRNA Sequencing and Assay in 2023 is US$ 0.34 billion, and is expected to reach US$ 0.94 billion by 2031 at a CAGR of 13.47%.

miRNA sequencing is a high-throughput DNA sequencing which is a parallel, next-generation sequencing technique used for microRNAs. It is different from other forms of RNA sequencing as the input material is augmented for small RNAs. miRNA sequencing permits researchers to understand tissue-specific expression patterns, isoforms of miRNA and disease associations and most importantly, to discover miRNAs that were previously uncharacterized.

The articulation of miRNA is primarily related to epithelial-mesenchymal change, BRCA transformations, insusceptible framework, malignant growth immature properties of microorganism in triple-negative bosom disease and androgen receptor articulation. With advancements in computational methodologies and genomics, the market in the Middle East
Africa is projected to soar significantly.

The miRNA sequencing approach gives a high-throughput sequencing that proportionate the procedure and simultaneously creating thousands of groupings. This sequencing technique can turn into an integral instrument in the prognostics and diagnostics division. The increasing frequency of development and malignant growth of examination exercises in the hereditary sector, rising demand for financially shrewd genome sequencing procedures are the factors that shall augment the market growth.

Very few miRNA therapeutics that can show conceivable results for the vascular ailment, Hepatitis C infection, cardiometabolic illness, fringe blood vessel ailment and other malignancies, are under different clinical preliminaries. These therapeutics have immense potential in preclinical examinations which are foreseen to bolster research and development in upcoming years.

The Middle East and Africa is one important region for the miRNA sequencing and assay market. Expansion of government support for genomic research, the proximity of world-class organizations dedicated to hereditary research, high-throughput miRNA examination procedures are some integral factors responsible for the market growth in the region. The increasing demand for miRNA sequencing and extensive hereditary research exercises are poised to significantly augment the market growth in the region.

  • Illumina, Inc.
  • Thermo Fisher Scientific
  • Qiagen, Perkinelmer, Inc.
  • Takara Bio, Inc.
  • New England Biolabs, Inc.
  • Norgen Biotek Corporation
  • Trilink Biotechnologies
  • Lexogen
  • Oxford Nanopore Technologies

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Sequencing Consumables
  • Library Preparation Kits

By Technology

  • Sequencing by Synthesis
  • Ion Semiconductor Sequencing
  • Sequencing by Oligonucleotide Ligation and Detection
  • Nanopore Sequencing

By End User

  • Research and Academic Institutes
  • Contract Research Organizations

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the MiRNA Sequencing and Assay Market By Product, By Technology, By End User And By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Asia Pacific, Europe, Latin America and Middle East and Africa
  • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • Profiling of companies to evaluate their market shares, strategies, financials and core competencies

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   MiRNA Sequencing and Assay Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of MiRNA Sequencing and Assay Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   MiRNA Sequencing and Assay Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   MiRNA Sequencing and Assay Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Sequencing Consumables
        2. Library Preparation Kits

  • 8.   MiRNA Sequencing and Assay Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Sequencing by Synthesis
        2. Ion Semiconductor Sequencing
        3. Sequencing by Oligonucleotide Ligation and Detection
        4. Nanopore Sequencing

  • 9.   MiRNA Sequencing and Assay Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Research and Academic Institutes
        2. Contract Research Organizations

  • 10.   North America MiRNA Sequencing and Assay Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America MiRNA Sequencing and Assay Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe MiRNA Sequencing and Assay Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific MiRNA Sequencing and Assay Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa MiRNA Sequencing and Assay Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Illumina, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Thermo Fisher Scientific
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Qiagen
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Perkinelmer, Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Takara Bio, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. New England Biolabs, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Norgen Biotek Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Trilink Biotechnologies
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Lexogen
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Oxford Nanopore Technologies
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients